Maxalt is a brand name for a medication whose active ingredient is rizatriptan. It is also known by its generic name, rizatriptan benzoate. Maxalt is used to treat migraine headaches, providing relief from pain, nausea, and sensitivity to light and sound.
The pricing structure for Maxalt is set between £5.7 and £9.2 for every pills. It’s reflective of the size of the packaging and ingredient concentration (4 or 48 mg).
Maxalt contains the active ingredient rizatriptan benzoate, which is a serotonin receptor agonist. It specifically targets the 5-HT1B/1D receptors to alleviate migraine symptoms. Rizatriptan, as a triptan class medication, is effective in controlling acute migraine attacks.
Maxalt is primarily indicated for the acute treatment of migraine attacks with or without aura in adults and children aged 6 to 17 years. This medication is not intended for use in the prophylactic treatment of migraines or for the management of cluster headaches.
Maxalt is available in two dosage forms: conventional tablets and orally disintegrating tablets (Maxalt-MLT). The conventional tablets are typically available in 5 mg and 10 mg strengths. Maxalt-MLT tablets also come in 5 mg and 10 mg concentrations and dissolve on the tongue without the need for water.
The initial recommended dose for adults is 5 mg or 10 mg, taken as soon as migraine symptoms appear. For children aged 6 to 17, the dose is typically 5 mg. If the migraine persists or returns after initial relief, an additional dose may be taken after at least 2 hours, not exceeding 30 mg in a 24-hour period.
Maxalt works by stimulating serotonin (5-HT) receptors in the brain, leading to vasoconstriction of the intracranial blood vessels. This action helps to alleviate headache pain and associated migraine symptoms such as nausea, photophobia, and phonophobia.
Rizatriptan is quickly absorbed after oral administration, with peak plasma concentrations reached within 1 to 1.5 hours. The bioavailability of the conventional tablet is approximately 45%, while that of Maxalt-MLT is slightly lower. Rizatriptan is metabolized primarily by monoamine oxidase-A (MAO-A) and excreted in the urine.
Concurrent use of Maxalt with other serotonin receptor agonists (triptans) is contraindicated due to the risk of additive vasospastic effects. Caution is advised when used with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) due to the potential for serotonin syndrome. The risk of significant interactions increases with MAO inhibitors, necessitating avoidance.
Common side effects of Maxalt include dizziness, fatigue, somnolence, and dry mouth. Serious side effects, although less common, may include chest pain, shortness of breath, and significant elevation of blood pressure. Any adverse reaction should be evaluated by a healthcare provider.
Maxalt should be stored at room temperature, away from moisture and heat. The tablets should remain in their original packaging until ready for use. For Maxalt-MLT, ensure the blister pack is not opened until use to maintain the tablet’s integrity.
For patients with moderate hepatic impairment, the maximum dose should be reduced to 5 mg due to reduced clearance of rizatriptan. Similarly, use caution with renally impaired patients as their condition may affect the drug’s excretion.
Clinical trials have demonstrated that Maxalt provides significant relief from migraine pain within two hours for a substantial percentage of patients. Both the conventional tablet and Maxalt-MLT forms have shown similar efficacy, though patient preference indicates variability in the onset of relief.
When using conventional Maxalt tablets, swallow the tablet whole with water. For Maxalt-MLT, place the orally disintegrating tablet on the tongue and allow it to dissolve completely before swallowing. No water is required for Maxalt-MLT.
Maxalt is approved for use in children aged 6 to 17 years for the acute treatment of migraines. The efficacy and safety in this age group have been verified, with the 5 mg dose generally recommended based on clinical studies.
In case of overdose, supportive care is the main treatment as there is no specific antidote for rizatriptan. Symptoms of overdose may include hypertension, dizziness, and somnolence. Immediate medical attention is required for overdose management.
Patients should be informed about the proper use of Maxalt, the importance of not exceeding the prescribed dosage, and potential side effects. Educate patients on recognizing signs of serious adverse reactions and instructing them to seek medical advice promptly if such symptoms occur.
The safety of Maxalt during pregnancy has not been well established. Pregnant women should only use Maxalt if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is essential before taking this medication during pregnancy.
Clinical trials have indicated no substantial differences in the efficacy of Maxalt in older adults compared to younger patients. However, increased sensitivity in some older individuals cannot be ruled out, necessitating cautious use. Adjustments in dosing may be required based on the individual’s response and health status.
Rizatriptan is excreted in human breast milk. Caution should be exercised when Maxalt is administered to a breastfeeding woman. Consideration should be given to the benefits of breastfeeding for the child and the medication’s potential benefits and risks for the nursing mother.
Maxalt should be prescribed to patients suffering from acute migraine attacks who have not achieved adequate relief with over-the-counter medications. A thorough medical history and understanding of the patient’s migraine pattern are essential for appropriate patient selection.